These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36335273)

  • 1. Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
    Clark NM; Roberts EA; Fedorenko C; Sun Q; Dubard-Gault M; Handford C; Yung R; Cheng HH; Sham JG; Norquist BM; Flanagan MR
    Ann Surg Oncol; 2023 Mar; 30(3):1312-1326. PubMed ID: 36335273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.
    Lorenzo Bermejo J; Hemminki K
    Ann Oncol; 2004 Dec; 15(12):1834-41. PubMed ID: 15550590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study.
    Taji T; Odan N; Kataoka Y; Ikeda M; Yamaguchi A; Suzuki E; Suwa H
    Breast Cancer; 2023 Mar; 30(2):309-314. PubMed ID: 36547869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
    Minoura Y; Takahashi M; Maeda H; Kuwahara S; Tachikawa H; Yamamoto M; Tomioka N; Watanabe K; Sakurai A
    Breast Cancer; 2022 Sep; 29(5):808-813. PubMed ID: 35641852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic Prostate Cancers.
    Shevach JW; Candelieri-Surette D; Lynch JA; Hubbard RA; Alba PR; Glanz K; Parikh RB; Maxwell KN
    J Natl Compr Canc Netw; 2024 Apr; 22(4):237-243. PubMed ID: 38631387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
    Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
    BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large US health care system.
    Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
    Clin Genet; 2022 Mar; 101(3):324-334. PubMed ID: 34927729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer genetic testing: NCCN familial high-risk assessment: breast/ovarian.
    Daly MB
    Can J Urol; 2019 Oct; 26(5 Suppl 2):29-30. PubMed ID: 31629424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients.
    Lumish HS; Steinfeld H; Koval C; Russo D; Levinson E; Wynn J; Duong J; Chung WK
    J Genet Couns; 2017 Oct; 26(5):1116-1129. PubMed ID: 28357778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
    Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
    Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer.
    Stoll S; Unger S; Azzarello-Burri S; Chappuis P; Graffeo R; Pichert G; Röthlisberger B; Taban F; Riniker S
    Swiss Med Wkly; 2021 Sep; 151():w30038. PubMed ID: 34519462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.
    Wong ES; Shekar S; Chan CH; Hong LZ; Poon SY; Silla T; Lin C; Kumar V; Davila S; Voorhoeve M; Thike AA; Ho GH; Yap YS; Tan PH; Tan MH; Ang P; Lee AS
    PLoS One; 2015; 10(7):e0134408. PubMed ID: 26221963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
    BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients.
    Seong MW; Kim KH; Chung IY; Kang E; Lee JW; Park SK; Lee MH; Lee JE; Noh DY; Son BH; Park HL; Cho SI; Park SS; ; Kim SW
    Breast Cancer Res Treat; 2014 Jul; 146(1):63-9. PubMed ID: 24894343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.
    Trivers KF; Baldwin LM; Miller JW; Matthews B; Andrilla CH; Lishner DM; Goff BA
    Cancer; 2011 Dec; 117(23):5334-43. PubMed ID: 21792861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
    Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
    Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of National Comprehensive Cancer Network guideline-based Tool for Risk Assessment for breast and ovarian Cancer (N-TRAC): A patient-reported survey for genetic high-risk assessment for breast and ovarian cancers in women.
    Ozanne EM; Howe R; Mallinson D; Esserman L; Van't Veer LJ; Kaplan CP
    J Genet Couns; 2019 Jun; 28(3):507-515. PubMed ID: 30663827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.